Scherl EJ - Search Results

1

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study.

Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KE. Danese S, et al. Among authors: scherl ej. Clin Gastroenterol Hepatol. 2021 Nov;19(11):2324-2332.e6. doi: 10.1016/j.cgh.2021.06.011. Epub 2021 Jun 12. Clin Gastroenterol Hepatol. 2021. PMID: 34126262 Clinical Trial.

2

Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease.

Schwartz LK, Kim MK, Coleman M, Lichtiger S, Chadburn A, Scherl E. Schwartz LK, et al. Clin Gastroenterol Hepatol. 2006 Aug;4(8):1030-4. doi: 10.1016/j.cgh.2006.05.024. Epub 2006 Jul 18. Clin Gastroenterol Hepatol. 2006. PMID: 16854631

3

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P; Ustekinumab Crohn's Disease Study Group. Sandborn WJ, et al. Gastroenterology. 2008 Oct;135(4):1130-41. doi: 10.1053/j.gastro.2008.07.014. Epub 2008 Jul 17. Gastroenterology. 2008. PMID: 18706417 Clinical Trial.

4

Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.

Scherl EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S, Mareya S, Forbes WP. Scherl EJ, et al. Am J Gastroenterol. 2009 Jun;104(6):1452-9. doi: 10.1038/ajg.2009.83. Epub 2009 Apr 21. Am J Gastroenterol. 2009. PMID: 19491859 Clinical Trial.

5

Ulcerative Colitis Care Pathway.

Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Dassopoulos T, et al. Among authors: scherl ej. Gastroenterology. 2015 Jul;149(1):238-45. doi: 10.1053/j.gastro.2015.05.036. Epub 2015 May 27. Gastroenterology. 2015. PMID: 26025078 Review. No abstract available.

6

Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.

Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, Hoffman G, Agrawal M, Lukin D, Desai A, McEachern E, Bosworth B, Scherl E, Reyes A, Zaidi H, Mudireddy P, DiCaprio D, Sultan K, Korelitz B, Wang E, Williams R, Chen L, Katz S, Itzkowitz S; New York Crohn's and Colitis Organization. Axelrad J, et al. Clin Gastroenterol Hepatol. 2016 Jan;14(1):58-64. doi: 10.1016/j.cgh.2015.07.037. Epub 2015 Aug 3. Clin Gastroenterol Hepatol. 2016. PMID: 26247164

7

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.

Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Arasaradnam RP, Sands BE, Marano C. Panaccione R, et al. Among authors: scherl ej. Aliment Pharmacol Ther. 2020 Dec;52(11-12):1658-1675. doi: 10.1111/apt.16119. Epub 2020 Oct 21. Aliment Pharmacol Ther. 2020. PMID: 33086438 Free PMC article. Clinical Trial.

8

Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.

Battat R, Lukin D, Scherl EJ, Pola S, Kumar A, Okada L, Yang L, Jain A, Siegel CA. Battat R, et al. Among authors: scherl ej. Inflamm Bowel Dis. 2021 Aug 19;27(9):1443-1451. doi: 10.1093/ibd/izaa313. Inflamm Bowel Dis. 2021. PMID: 33252119

9

Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Ahmed W, Galati J, Kumar A, Christos PJ, Longman R, Lukin DJ, Scherl E, Battat R. Ahmed W, et al. Clin Gastroenterol Hepatol. 2022 Mar;20(3):e361-e379. doi: 10.1016/j.cgh.2021.03.034. Epub 2021 Mar 31. Clin Gastroenterol Hepatol. 2022. PMID: 33798711 Review.

10

Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy.

Volger S, Scherl E. Volger S, et al. Clin Gastroenterol Hepatol. 2022 Apr;20(4):962-963. doi: 10.1016/j.cgh.2021.04.015. Epub 2021 Apr 20. Clin Gastroenterol Hepatol. 2022. PMID: 33864935 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

126 results

Search Page